Brought to you by 
SmithKline in $125 million deal with Human Genome Sciences
May 1993
Executive Summary
SmithKline Beecham will receive exclusive, worldwide rights to almost all human and animal health care applications of Human Genome Sciences' gene sequencing technology, under a long-term agreement potentially worth $125mm to HGS.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SmithKline in $125 million deal with Human Genome Sciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice